Glycyrrhizin prevents SARS-CoV-2 S1 and Orf3a induced high mobility group box 1 (HMGB1) release and inhibits viral replication.


Journal

Cytokine
ISSN: 1096-0023
Titre abrégé: Cytokine
Pays: England
ID NLM: 9005353

Informations de publication

Date de publication:
06 2021
Historique:
received: 01 11 2020
revised: 04 03 2021
accepted: 05 03 2021
pubmed: 28 3 2021
medline: 20 4 2021
entrez: 27 3 2021
Statut: ppublish

Résumé

Efforts to understand host factors critical for COVID-19 pathogenesis have identified high mobility group box 1 (HMGB1) to be crucial for regulating susceptibility to SARS-CoV-2. COVID-19 disease severity is correlated with heightened inflammatory responses, and HMGB1 is an important extracellular mediator in inflammation processes.In this study, we evaluated the effect of HMGB1 inhibitor Glycyrrhizin on the cellular perturbations in lung cells expressing SARS-CoV-2 viral proteins. Pyroptosis in lung cells transfected with SARS-CoV-2 S-RBD and Orf3a, was accompanied by elevation of IL-1β and extracellular HMGB1 levels. Glycyrrhizin mitigated viral proteins-induced lung cell pyroptosis and activation of macrophages. Heightened release of proinflammatory cytokines IL-1β, IL-6 and IL-8, as well as ferritin from macrophages cultured in conditioned media from lung cells expressing SARS-CoV-2 S-RBD and Orf3a was attenuated by glycyrrhizin. Importantly, Glycyrrhizin inhibited SARS-CoV-2 replication in Vero E6 cells without exhibiting cytotoxicity at high doses. The dual ability of Glycyrrhizin to concomitantly halt virus replication and dampen proinflammatory mediators might constitute a viable therapeutic option in patients with SARS-CoV-2 infection.

Identifiants

pubmed: 33773396
pii: S1043-4666(21)00076-4
doi: 10.1016/j.cyto.2021.155496
pmc: PMC7953444
pii:
doi:

Substances chimiques

HMGB1 Protein 0
HMGB1 protein, human 0
ORF3a protein, SARS-CoV-2 0
Spike Glycoprotein, Coronavirus 0
Viroporin Proteins 0
spike protein, SARS-CoV-2 0
Glycyrrhizic Acid 6FO62043WK

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

155496

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Références

Pharmacol Ther. 2014 Mar;141(3):347-57
pubmed: 24220159
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
Annu Rev Immunol. 2011;29:139-62
pubmed: 21219181
Mol Med. 2020 May 7;26(1):42
pubmed: 32380958
Rheumatology (Oxford). 2016 Dec;55(12):2260-2270
pubmed: 27632996
Annu Rev Immunol. 2009;27:451-83
pubmed: 19105661
PLoS One. 2011;6(5):e19705
pubmed: 21611183
Clin Immunol. 2020 Jun;215:108448
pubmed: 32353634
Cell Signal. 2013 Mar;25(3):682-9
pubmed: 23220408
Heliyon. 2020 Dec 07;6(12):e05672
pubmed: 33313438
J Immunol. 2020 Jul 15;205(2):307-312
pubmed: 32493814
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Int Immunol. 2017 Nov 1;29(9):401-409
pubmed: 28541437
J Interferon Cytokine Res. 2012 Apr;32(4):169-77
pubmed: 22280057
Immunol Rev. 2017 May;277(1):61-75
pubmed: 28462526
Nucleic Acids Res. 1994 Jul 11;22(13):2678-86
pubmed: 8041631
J Cell Sci. 2007 Mar 1;120(Pt 5):772-81
pubmed: 17284521
J Exp Med. 2000 Aug 21;192(4):565-70
pubmed: 10952726
F1000Res. 2020 Jun 23;9:
pubmed: 32595947
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Pediatr Res. 2018 May;83(5):1049-1056
pubmed: 29329282
Semin Immunopathol. 2016 Jul;38(4):471-82
pubmed: 26965109
J Leukoc Biol. 2005 Jul;78(1):1-8
pubmed: 15734795
Cell Death Dis. 2019 Oct 14;10(10):778
pubmed: 31611559
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
J Gastroenterol Hepatol. 2002 Nov;17(11):1198-204
pubmed: 12453280
Cell. 2021 Jan 7;184(1):76-91.e13
pubmed: 33147444
J Immunol. 2018 Nov 1;201(9):2753-2766
pubmed: 30275049
mBio. 2018 May 22;9(3):
pubmed: 29789363
J Immunol. 2008 Feb 15;180(4):2531-7
pubmed: 18250463
Blood. 2010 Sep 2;116(9):1574-84
pubmed: 20472835
Lancet. 2003 Jun 14;361(9374):2045-6
pubmed: 12814717
Carcinogenesis. 2013 Feb;34(2):388-96
pubmed: 23125226
Cytokine. 2011 Nov;56(2):180-7
pubmed: 21862344
Mol Cell Biol. 2018 Apr 16;38(9):
pubmed: 29463646
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Antimicrob Agents Chemother. 2020 Sep 21;64(10):
pubmed: 32759267
J Leukoc Biol. 2007 Jan;81(1):1-5
pubmed: 17032697
J Biol Chem. 1990 Aug 25;265(24):14572-8
pubmed: 1696948
Chem Biol. 2007 Apr;14(4):431-41
pubmed: 17462578
Lancet. 2020 Jun 6;395(10239):1741-1743
pubmed: 32410759
Trials. 2020 Nov 23;21(1):943
pubmed: 33225970

Auteurs

Pruthvi Gowda (P)

National Brain Research Centre, Manesar, Gurugram, Haryana 122 052, India.

Shruti Patrick (S)

National Brain Research Centre, Manesar, Gurugram, Haryana 122 052, India.

Shanker Datt Joshi (SD)

National Brain Research Centre, Manesar, Gurugram, Haryana 122 052, India.

Rajesh Kumar Kumawat (RK)

National Brain Research Centre, Manesar, Gurugram, Haryana 122 052, India.

Ellora Sen (E)

National Brain Research Centre, Manesar, Gurugram, Haryana 122 052, India. Electronic address: ellora@nbrc.ac.in.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH